Torsdag, 9 juli 2015
AstraZeneca announced today that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. Entocort is currently available in over 40 countries, with total product sales of $53 million outside the US in 2014. A regulatory submission for Entocort in Japan is anticipated in the coming months.
Under the terms of the agreement, Tillotts will pay AstraZeneca $215 million upon completion of the transaction to acquire the rights to sell and develop Entocort capsules and enema formulations outside the US. The transaction does not include the transfer of any AstraZeneca employees or facilities.
Luke Miels, Executive Vice President, Global Product and Portfolio Strategy and Corporate Affairs, AstraZeneca, said: “Our agreement with Tillotts reinforces our strategic focus on selected therapy areas and puts this important medicine in the hands of a company with specialist expertise in gastroenterology, which will benefit patients.”
Thomas A. Tóth von Kiskér, CEO of Tillotts, commented: “Entocort perfectly complements our Asacol® portfolio marketed in 50 countries worldwide through our own European affiliates, our Japanese parent company Zeria Pharmaceutical and our trusted network of marketing partners. This acquisition underscores our commitment to continue to position Tillotts as a leading European specialised player in the field of gastroenterology, offering patients a wide range of treatments for the GI tract.”
Sachiaki Ibe, Chairman and CEO of Zeria Pharmaceutical, added: “We are excited to obtain a well-established brand such as Entocort and to expand its commercial reach to Japan and other countries. With this move, we confirm our expansion strategy of organic growth combined with merger and acquisition activities, while delivering increased value to our shareholders."
As AstraZeneca will no longer retain an interest in the ex-US rights to Entocort, the upfront receipt will be reported in Other Operating Income in the Company’s financial statements for 2015. The transaction is expected to complete in the second half of 2015, subject to customary closing conditions, and it does not impact AstraZeneca’s financial guidance for 2015.
NOTES TO EDITORS
In capsule formulation, Entocort is a first-line therapy indicated for the induction and maintenance of clinical remission of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. As an enema, Entocort is indicated for the induction and maintenance of clinical remission of distal ulcerative colitis in the rectum, sigmoid colon and descending colon.
AstraZeneca has a partnership with Par Pharmaceutical for the commercialisation of Entocort in the US.
Tillotts Pharma AG, part of the Zeria Group, is a fast-growing specialty pharma company with over 200 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products, medical devices and diagnostics, all in the field of gastroenterology.
Tillotts successfully markets its own products Asacol® and Colpermin®, as well as VistaPrep® and in-licensed products, such as Simtomax®, in over 55 countries through its own affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world. For more information, please visit www.tillotts.com.
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information, please visit www.zeria.co.jp
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Esra Erkal-Paler||UK/Global||+44 20 7604 8030|
|Vanessa Rhodes||UK/Global||+44 20 7604 8037|
|Ayesha Bharmal||UK/Global||+44 20 7604 8034|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+ 1 302 885 6351|
|Name||Area||Phone Number||Mobile Phone Number|
|Thomas Kudsk Larsen||+44 20 7604 8199||+44 7818 524185|
|Eugenia Litz||Respiratory, Inflammation and Autoimmunity||+44 20 7604 8233||+44 7884 735627|
|Nick Stone||Cardiovascular and Metabolic Disease||+44 17 6326 3994||+44 7717 618834|
|Karl Hård||Oncology||+44 20 7604 8123||+44 7789 654364|
|Craig Marks||Infection, Neuroscience and Gastrointestinal Disease||+44 20 7604 8591||+44 7881 615764|
|Christer Gruvris||+44 20 7604 8126||+44 7827 836825|
Dial / Toll-Free, +1 301 398 3251, +1 866 381 7277